Business Description
Alligator Bioscience AB
ISIN : SE0024173637
Total Employee Number:
11Compare
Compare
Traded in other countries / regions
ATORX.Sweden7AL0.Germany0RK9.UK IPO Date
2016-11-30Description
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.02 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.78 | |||||
Debt-to-EBITDA | -1.87 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -17.79 | |||||
Beneish M-Score | 144.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -85.8 | |||||
3-Year EBITDA Growth Rate | 82.3 | |||||
3-Year EPS without NRI Growth Rate | 45.4 | |||||
3-Year FCF Growth Rate | 43.8 | |||||
3-Year Book Growth Rate | -88.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 192.84 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.96 | |||||
9-Day RSI | 76.31 | |||||
14-Day RSI | 63.07 | |||||
3-1 Month Momentum % | -35.03 | |||||
6-1 Month Momentum % | -14.15 | |||||
12-1 Month Momentum % | -93.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.76 | |||||
Quick Ratio | 1.76 | |||||
Cash Ratio | 1.09 | |||||
Days Sales Outstanding | 205.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -283 | |||||
Shareholder Yield % | -135.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -15677.43 | |||||
Net Margin % | -8086.38 | |||||
EBITDA Margin % | -3376.65 | |||||
FCF Margin % | -22013.42 | |||||
OCF Margin % | -22013.42 | |||||
ROA % | -47.51 | |||||
ROIC % | -71.51 | |||||
3-Year ROIIC % | 440.93 | |||||
ROC (Joel Greenblatt) % | -290.85 | |||||
ROCE % | -70.91 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 26.12 | |||||
PB Ratio | 2.77 | |||||
EV-to-EBIT | -18.96 | |||||
EV-to-EBITDA | -6.84 | |||||
EV-to-Revenue | 231.02 | |||||
EV-to-FCF | -0.98 | |||||
Price-to-GF-Value | 18.92 | |||||
Earnings Yield (Greenblatt) % | -5.27 | |||||
FCF Yield % | -94.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alligator Bioscience AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.514 | ||
| EPS (TTM) (kr) | -0.864 | ||
| Beta | 1.8346 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 90.87 | ||
| 14-Day RSI | 63.07 | ||
| 14-Day ATR (kr) | 0.003389 | ||
| 20-Day SMA (kr) | 0.17194 | ||
| 12-1 Month Momentum % | -93.71 | ||
| 52-Week Range (kr) | 0.159 - 3.057193 | ||
| Shares Outstanding (Mil) | 628.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alligator Bioscience AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alligator Bioscience AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 15:00 | In 100 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 08:00 | In 100 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-10 15:00 | 0.18 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-07-10 08:00 | 0.18 (+0.00%) | ||
| General meeting for 2026 | 2026-05-06 10:00 | 0.22 (-4.42%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 13:00 | 0.21 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 08:00 | 0.21 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 0.18 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-12 15:00 | 0.20 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 08:00 | 0.20 (+0.00%) |
Show
Entries
Alligator Bioscience AB Frequently Asked Questions
What is Alligator Bioscience AB(LTS:0RK9)'s stock price today?
The current price of LTS:0RK9 is kr0.19. The 52 week high of LTS:0RK9 is kr3.06 and 52 week low is kr0.16.
When is next earnings date of Alligator Bioscience AB(LTS:0RK9)?
The next earnings date of Alligator Bioscience AB(LTS:0RK9) is 2026-10-23 Est..
Does Alligator Bioscience AB(LTS:0RK9) pay dividends? If so, how much?
Alligator Bioscience AB(LTS:0RK9) does not pay dividend.
Press Release
Articles on Alligator Bioscience AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers